Combination immunotherapy anti-PD-1 antibody with CBT-101 (c-MET inhibitor) demonstrates enhanced activity in tumors not dependent on c-MET
CBT-102, an oral multi-kinase small molecule, demonstrates favorable activity in LIMsh050 and PLCPRF5 human hepatocellular carcinoma animal models and cardiac safety in rabbit Purkinje and Beagle dogs compared to sorafenib
A phase 1 multicenter, dose escalation study of CBT-501, a novel anti-PD-1 inhibitor in subjects with select advanced or relapsed/recurrent solid tumors
CBT-502 (TQB2450), a novel anti-PD-L1 antibody, demonstrates favorable activity in MC-38/H-11 murine colon and A375 human melanoma animal models
Bozitinib, a highly selective inhibitor of c-MET, demonstrates robust activity in gastric, lung, hepatic and pancreatic in vivo models
CBT-501, a novel humanized anti-PD-1 antibody shows differentiated activity in a humanized genetically engineered mouse model of colon carcinoma
